Synairgen surges as US Covid-19 study advances to final stage trials
Shares in respiratory drug development company Synairgen (SNG:AIM) rallied 13% to 166.4p after a US study recommended its inhalation treatment for severe viral lung infections should advance to final stage trials.Although Synairgen...
20 October 2021